Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.
Doug Janzen announced the acquisition of 100,000 Common Shares in Aequus Pharmaceuticals on July 19, 2022, through the TSX Venture Exchange. He purchased 99,000 shares at $0.07 each and 1,000 shares at $0.08, totaling $7,010. Following a prior issuance of shares, Janzen's ownership fell below 10%, exempting him from early warning requirements under NI 62-103. After the acquisition, he held approximately 9.08% of total outstanding shares. The acquisition was made for investment purposes, and further early warning reports will only be filed if his holdings exceed 10%.
- Janzen's acquisition signals confidence in Aequus's future.
- The purchase was made at low share prices, potentially advantageous for investors.
- Janzen's ownership remains below 10%, indicating potential dilution concerns.
- The prior issuance of shares led to a decrease in his percentage ownership.
VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the “Acquisition”) of 100,000 common shares (“Common Shares”) in the capital of Aequus Pharmaceuticals Inc. (Address: 2820 – 200 Granville St., Vancouver, BC V6C 1S4) (“Aequus”) through the facilities of the TSX Venture Exchange. Mr. Janzen acquired 99,000 Common Shares at a price of
As previously announced by Aequus, on February 12, 2021, Aequus issued Common Shares from treasury (the “Issuance”). Following the Issuance, the beneficial ownership of Mr. Janzen in Common Shares of Aequus, being the securities subject to the most recent report required to be filed by Mr. Janzen in respect of Aequus under National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”), fell below
Prior to the Acquisition, Mr. Janzen owned, directly or indirectly, or exercised control or direction over, 11,953,800 Common Shares and 300,000 stock options (“Options”), with each Option entitling Mr. Janzen to acquire one Common Share. The Common Shares represented approximately
After the Acquisition of the 100,000 Common Shares, Mr. Janzen now owns, directly or indirectly, or exercises control or direction over, 12,053,800 Common Shares, representing approximately
The Acquisition was made for investment purposes. In accordance with applicable securities laws, Mr. Janzen may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, “Securities”) of Aequus in the open market or otherwise, and reserves the right to dispose of any or all of his Securities in the open market or otherwise at any time and from time to time and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of Aequus and other relevant factors.
As Mr. Janzen no longer holds
The early warning report (exit) relating to the transactions contemplated hereby will be filed on the System for Electronic Document Analysis and Review under Aequus’ profile on www.sedar.com.
For more information, or to obtain a copy of the subject early warning report, please contact:
Doug Janzen
2820 – 200 Granville St.
Vancouver, British Columbia
V6C 1S4
Telephone: 604-336-7906
![](https://ml.globenewswire.com/media/NDlkMmM0YzMtYWYzYy00OTYyLTk0NzYtMGU4N2E1ZmEzNzQ1LTExMDE3ODg=/tiny/Aequus-Pharmaceuticals.png)
FAQ
What was the price paid by Doug Janzen for Aequus shares?
How many shares does Doug Janzen own after the acquisition?
What percentage of Aequus shares does Doug Janzen control now?
Will Doug Janzen file further early warning reports?